These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 17364594

  • 41. Hormone therapy and cardiovascular disease.
    Chen FP.
    Taiwan J Obstet Gynecol; 2006 Dec; 45(4):287-93. PubMed ID: 17175484
    [Abstract] [Full Text] [Related]

  • 42. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
    Oelkers W.
    Mol Cell Endocrinol; 2004 Mar 31; 217(1-2):255-61. PubMed ID: 15134826
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Drospirenone in HRT?
    Drug Ther Bull; 2009 Apr 31; 47(4):41-4. PubMed ID: 19357298
    [Abstract] [Full Text] [Related]

  • 45. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention.
    Vitale C, Miceli M, Rosano GM.
    Climacteric; 2007 Oct 31; 10 Suppl 2():16-20. PubMed ID: 17882667
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women.
    Villa P, Suriano R, Ricciardi L, Tagliaferri V, De Cicco S, De Franciscis P, Colacurci N, Lanzone A.
    Fertil Steril; 2011 Jan 31; 95(1):158-63. PubMed ID: 20728082
    [Abstract] [Full Text] [Related]

  • 48. The effect of estradiol valerate and dienogest combination on serum homocysteine levels in postmenopausal women: a clinical trial.
    Pirimoglu ZM, Aygun E, Dansuk R, Kucukercan I, Unal O, Turan C.
    Gynecol Endocrinol; 2005 Sep 31; 21(3):185-8. PubMed ID: 16335913
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. [Cardiovascular disease as a current threat of older women. Relation to estrogens].
    Zárate A, Saucedo R, Basurto L, Martínez C.
    Ginecol Obstet Mex; 2007 May 31; 75(5):286-92. PubMed ID: 17849811
    [Abstract] [Full Text] [Related]

  • 51. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator.
    Campisi R, Marengo FD.
    Cardiovasc Drug Rev; 2007 May 31; 25(2):132-45. PubMed ID: 17614936
    [Abstract] [Full Text] [Related]

  • 52. [Hypertension and menopause].
    Masszi G.
    Orv Hetil; 2002 Dec 22; 143(51):2821-8. PubMed ID: 12638308
    [Abstract] [Full Text] [Related]

  • 53. Alternatives for optimal hormone replacement therapy.
    Sitruk-Ware R.
    Climacteric; 2003 Aug 22; 6 Suppl 2():11-6. PubMed ID: 14669839
    [Abstract] [Full Text] [Related]

  • 54. Hypertension in women.
    Pimenta E.
    Hypertens Res; 2012 Feb 22; 35(2):148-52. PubMed ID: 22129517
    [Abstract] [Full Text] [Related]

  • 55. Why is cardiovascular health important in menopausal women?
    Simon T.
    Climacteric; 2006 Sep 22; 9 Suppl 1():13-8. PubMed ID: 16899439
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. The metabolic and cardiovascular consequences of HRT.
    Stevenson JC.
    Br J Clin Pract; 1995 Sep 22; 49(2):87-90. PubMed ID: 7779651
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.